Calcitonin is a peptide hormone made by the thyroid that helps lower blood calcium. A lab-made copy of the salmon version was long used for osteoporosis, but its role has shrunk. In July 2012 the European Medicines Agency told doctors to stop prescribing the nasal spray for osteoporosis after a review found slightly higher cancer rates, and the U.S. label for the injection now limits it to people for whom other treatments are not suitable.
The receptor is back in focus because of obesity drugs. Amylin acts in part through the calcitonin receptor, and some amylin-based drugs activate both receptors, including Novo Nordisk's cagrilintide, one half of CagriSema. Viking Therapeutics started a Phase 1 trial of VK3019, a dual amylin and calcitonin receptor agonist, in the second quarter of 2026. On October 6, 2026, a University of Pennsylvania team described a brain circuit in mice and rats through which calcitonin-receptor neurons curb eating.
See #amylin, #cagrilintide, and #petrelintide.
A University of Pennsylvania psychiatry team reported in Diabetes, Obesity and Metabolism on October 6, 2026 that neurons carrying the amylin-responsive calcitonin receptor in the laterodorsal tegmental nucleus, a brainstem region tied to reward and motivation, project to the ventral tegmental area in both mice and rats. Knocking down the receptor along that pathway weakened the appetite-suppressing effect of injected salmon calcitonin, which activates amylin receptors, and chemically switching the pathway on reduced food intake and body weight in mice. The findings come from rodents and help explain how amylin signaling reduces food intake.
Viking Therapeutics (NASDAQ: VKTX) disclosed on the July 29, 2026 Q2 2026 earnings call that VK3019, a novel dual amylin and calcitonin receptor agonist peptide for obesity, has entered Phase 1 clinical development. The candidate extends the company's obesity pipeline beyond the flagship VK2735 (dual GLP-1/GIP agonist). VK2735 status: Phase 3 VANQUISH program in obesity and obesity/type 2 diabetes is fully enrolled and advancing on track; oral VK2735 Phase 3 trials are slated to initiate in Q4 2026, positioning Viking as a potential first-to-market oral dual GLP-1/GIP agonist. A novel maintenance dosing study for VK2735 is nearing completion, with results expected later in Q3 2026 exploring less frequent dosing regimens. Q2 2026 financials: net loss widened to $128.1 million from $65.6 million in Q2 2025 on increased R&D spending, with $502 million in cash and short-term investments down from $706 million at year-end 2025. VK3019 is mechanistically distinct from VK2735: amylin signaling adds brainstem-mediated satiety (via the calcitonin receptor complex with RAMPs) on top of a calcitonin receptor agonism that has a longer development history in postmenopausal osteoporosis (Miacalcin) and Paget's disease. The amylin plus calcitonin combination extends the amylin-analog obesity category anchored by Novo Nordisk's cagrilintide (a component of CagriSema) and the Novo amycretin oral amylin monotherapy program.
Pep2Tango Therapeutics presented preclinical data on PTT-A, a novel long-acting unimolecular peptide tetra-agonist activating the GLP-1, GIP, amylin, and calcitonin receptors simultaneously, in a Medscape 'Moving Beyond GLP-1s' feature drawing from the ADA 2026 session 'Novel Strategies for Obesity Pharmacology' (oral abstracts 85-OR and 299-OR, Diabetes journal supplement). In 21-day chronic studies in diet-induced obese rats, the higher PTT-A dose achieved 19% body weight reduction versus the vehicle, compared to 12% each for tirzepatide and cagrilintide + semaglutide (CagriSema). Body composition analysis showed fat-mass loss without lean-mass loss, distinguishing PTT-A's profile from tirzepatide's documented muscle-loss pattern. PTT-A also showed robust glucose lowering, plasma lipid improvement, insulin sensitization, and liver-fat benefits.
Eli Lilly, with the Indiana Biosciences Research Institute, has disclosed an ADA Scientific Sessions Late-Breaking Poster slot (Poster 2839-LB, May 29) for a single peptide molecule that simultaneously activates five receptors: GLP-1, GIP, glucagon, amylin, and calcitonin. Lead investigator Jonathan Douros, PhD, will present rodent data showing weight-loss superiority over retatrutide in Lilly-sponsored animal studies. The compound is distinct from the DiMarchi/Tschöp/Müller GLP-1R/GIPR/PPARα/γ/δ quintuple agonist published in Nature on April 30 — that one is a peptide-drug conjugate combining GLP-1/GIP with the pan-PPAR agonist lanifibranor, while the Lilly + Indiana Biosciences molecule appears to be a single peptide hitting all five receptors directly. Both signal that the obesity-pharmacology ceiling is moving past the triple-agonist generation.